Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
$42.07-0.85%
Close 2026-09-09 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-09
Broken: Primary pillar broken — Operating margin improves to ~15% in 2026: FY26 guidance -20.0% to -50.0% vs 15.0% target.
Supernus is growing revenue fast, with 39% growth in Q1 2026. The company reaffirmed 2026 revenue guidance near $855 million. Operating income is improving from a loss of $10.3M to $8.3M loss in Q1 2026. The recent acquisition may add to growth and help profitability.
Supernus is still loss-making with weak profit margins. Earnings missed recently and operating losses remain large. The creation of a financial obligation under the CVR agreement adds risk. Revenue growth may slow and profitability may not improve as hoped.
The stock trades about 38% above our fair value near $34. Analysts expect 20% revenue growth. Our model sees slower EPS growth, so the price is stretched versus fundamentals.
Breaks if: Material cash flow strain or credit downgrade due to CVR obligation
Breaks if: Operating margin remains negative below 0% in FY26
Breaks if: Annual revenue falls below $695 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on growth and strategic mergers. The current thesis state is mixed, as the company is navigating challenges while attempting to leverage its merger with Indivior Pharmaceuticals for future growth.
The market seems to have priced in a low level of fragility, with expectations indicating a slight divergence from peers. SUPN is currently seen as having a durable premium compared to its industry counterparts.
Management is focused on driving growth in key commercial products, which has shown positive results recently. However, the company remains loss-making, and the near-term risks include potential earnings misses, though the probability is relatively low.
The thesis hinges on the successful completion of the merger with Indivior and the ability to maintain momentum in key product growth. Additionally, external factors like sector performance and economic indicators will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, SUPN's multi-year view is cautious but optimistic, dependent on strategic execution and market conditions. Not investment advice.